OpenClinica, LLC has announced that Rockville, MD-based KAI Research, Inc., (KAI), an Altarum Company, has selected the OpenClinica Enterprise Edition to power Phase I – IV clinical trials. Founded in 1986, KAI is a full service contract research organization (CRO) that provides innovative, cost-effective, and practical support to pharmaceutical, biotech and academic institutions, and the National Institutes of Health (NIH).
The OpenClinica software enhances clinical trials by streamlining electronic data capture (EDC) and clinical data management. The result is higher quality and faster access to the data.
“KAI is a CRO that relies on cutting edge information technology to help deliver the greatest value to our clients,” states Patti Shugarts, chief operating officer at KAI. She continues: “OpenClinica’s powerful technology and flexible model enable us to deploy a cutting edge EDC that meets the needs of both our industry and government clients.”
The OpenClinica clinical trial software is provided under a commercial open source model, and available in two editions. The OpenClinica Community Edition software is freely available under a widely accepted open source license. The OpenClinica Enterprise Edition consists of a fully validated version of the open source technology with additional capabilities, services, and resource ideal for mission critical research and highly regulated environments. The OpenClinica software is currently in use at over 500 biopharma sponsors, CROs, academic centers, and government agencies worldwide.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.